CoChat

A phase I study assessing the safety, tolerability, immunogenicity, and low-density lipoprotein cholesterol-lowering activity of immunotherapeutics targeting PCSK9

Open access
Zeitlinger, Markus, Bauer, Martin, Reindl-Schwaighofer, Roman, Stoekenbroek, Robert M., Lambert, Gilles, Berger-Sieczkowski, Evelyn, Lagler, Heimo, Oesterreicher, Zoe, Wulkersdorfer, Beatrix, Lührs, Petra, Galabova, Gergana, Schwenke, Carsten, Mader, Robert M., Medori, Rossella, Landlinger, Christine, Kutzelnigg, Alexandra, Staffler, Günther · 2021 · European Journal of Clinical Pharmacology
Cited by 57

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Abstract

Purpose: AT04A and AT06A are two AFFITOPE® peptide vaccine candidates being developed for the treatment of hypercholesterolemia by inducing proprotein convertase subtilisin/kexin type 9 (PCSK9)-specific antibodies. This study aimed to investigate safety, tolerability, antibody development, and reduction of low-density lipoprotein cholesterol (LDLc) following four subcutaneous immunizations. Methods: This phase I, single-blind, randomized, placebo-controlled study was conducted in a total of 72 healthy subjects with a mean fasting LDLc level at baseline of 117.1 mg/dL (range 77–196 mg/dL). Each cohort enrolled 24 subjects to receive three priming immunizations at weeks 0, 4, and 8 and to receive a single booster immunization at week 60 of either AT04A, AT06A, or placebo. In addition to safety (primary objective), the antigenic peptide- and PCSK9-specific antibody response and the impact on LDLc were evaluated over a period of 90 weeks. Results: The most common systemic treatment-related adverse events (AEs) reported were fatigue, headache, and myalgia in 75% of subjects in the AT06A group and 58% and 46% of subjects in the placebo and AT04A groups, respectively. Injection site reactions (ISR) representing 63% of all treatment-emergent adverse events (TEAEs), were transient and mostly of mild or moderate intensity and rarely severe (3%). Both active treatments triggered a robust, long-lasting antibody response towards the antigenic peptides used for immunization that optimally cross-reacted with the target epitope on PCSK9. In the AT04A group, a reduction in serum LDLc was observed with a mean peak reduction of 11.2% and 13.3% from baseline compared to placebo at week 20 and 70 respectively, and over the whole study period, the mean LDLc reduction for the AT04A group vs. placebo was −7.2% (95% CI [−10.4 to −3.9], P < 0.0001). In this group, PCSK9 target epitope titers above 50 were associated with clinically relevant LDLc reductions with an individual maximal decrease of 39%. Conclusions: Although both AT04A and AT06 were safe and immunogenic, only AT04A demonstrated significant LDLc-lowering activity, justifying further development. Trial registration: EudraCT: 2015-001719-11. ClinicalTrials.gov Identifier: NCT02508896.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s00228-021-03149-2

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

See all 57

Metadata

Authors
Zeitlinger, M., Bauer, M., Reindl-Schwaighofer, R., Stoekenbroek, R. M., Lambert, G., Berger-Sieczkowski, E., Lagler, H., Oesterreicher, Z., Wulkersdorfer, B., Lührs, P., Galabova, G., Schwenke, C., Mader, R. M., Medori, R., Landlinger, C., Kutzelnigg, A., & Staffler, G.
Venue
European Journal of Clinical Pharmacology
Published
2021-05-10
Volume
77
Issue
10
Pages
1473-1484
ISSN
  • 0031-6970 (ISSN-L)
  • 1432-1041
OpenAlex
W3163316465
Cited by
57
References
9
FWCI
9.32
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A phase I study assessing the safety, tolerability, immunogenicity, and low-density lipoprotein cholesterol-lowering activity of immunotherapeutics targeting PCSK9. https://app.cochat.ai/papers/10.1007/s00228-021-03149-2
The paper
Zeitlinger, M., Bauer, M., Reindl-Schwaighofer, R., Stoekenbroek, R. M., Lambert, G., Berger-Sieczkowski, E., Lagler, H., Oesterreicher, Z., Wulkersdorfer, B., Lührs, P., Galabova, G., Schwenke, C., Mader, R. M., Medori, R., Landlinger, C., Kutzelnigg, A., & Staffler, G. (2021). A phase I study assessing the safety, tolerability, immunogenicity, and low-density lipoprotein cholesterol-lowering activity of immunotherapeutics targeting PCSK9. European Journal of Clinical Pharmacology. https://doi.org/10.1007/s00228-021-03149-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.